Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization

Gennaro Chiappetta, Nicole Fabien, Alessandro Picone, Daniela Califano, Carmen Monaco, Vittorio De Franciscis, Giancarlo Vecchio, Giovanni Santelli

Research output: Contribution to journalArticle

Abstract

We have previously generated transgenic mice bearing a molecular construct obtained by fusing the rat thyroglobulin promoter with the human Kirsten ras oncogene (KRAS). These mice showed thyroid abnormalities, although at very low incidence and after a long latency period. A six-month thyrotropin (TSH) stimulation of thyroid glands, followed by a two-month suspension, induced a significant increase in the number of lesions in transgenic mice as compared with a nontransgenic control group. Our goal was to follow the progression and the reversion of the tumorigenesis process in relationship with the levels of expression of the KRAS in this experimental model. In situ hybridization was used to detect expression of KRAS mRNA in sections of thyroids of the various groups of mice. A positive hybridization was observed in follicular cells of TSH-stimulated transgenic mice, whereas no expression could be appreciated in control nontransgenic mice. A positive signal was also observed in thyroid glands excised from transgenic mice after the 2- month suspension of treatment; however, the number of expressing cells was decreased compared with transgenic mice killed immediately after 6 months of a goitrogen regimen. Finally, every cell in the single thyroid carcinoma observed after the two-month suspension was positive for the transgene mRNA. This study further strengthens the role of the expression of mutated KRAS in the early stages of thyroid follicular cell transformation and indicates that when the expression of the mutated KRAS becomes independent of exogenous TSH stimulation, this event coincides with a further progression towards tumorigenesis.

Original languageEnglish
Pages (from-to)85-93
Number of pages9
JournalOncology Research
Volume8
Issue number2
Publication statusPublished - 1996

Fingerprint

ras Genes
Thyroglobulin
Oncogenes
Transgenic Mice
In Situ Hybridization
Thyroid Gland
Suspensions
Carcinogenesis
Thyrotrophs
Antithyroid Agents
Messenger RNA
Thyrotropin
Transgenes
Thyroid Neoplasms
Theoretical Models
Cell Count
Control Groups
Incidence

Keywords

  • in situ hybridization
  • KRAS
  • thyroid
  • transgenic mice

ASJC Scopus subject areas

  • Cancer Research

Cite this

Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter : KRAS expression in thyroids analyzed by in situ hybridization. / Chiappetta, Gennaro; Fabien, Nicole; Picone, Alessandro; Califano, Daniela; Monaco, Carmen; De Franciscis, Vittorio; Vecchio, Giancarlo; Santelli, Giovanni.

In: Oncology Research, Vol. 8, No. 2, 1996, p. 85-93.

Research output: Contribution to journalArticle

Chiappetta, G, Fabien, N, Picone, A, Califano, D, Monaco, C, De Franciscis, V, Vecchio, G & Santelli, G 1996, 'Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization', Oncology Research, vol. 8, no. 2, pp. 85-93.
Chiappetta, Gennaro ; Fabien, Nicole ; Picone, Alessandro ; Califano, Daniela ; Monaco, Carmen ; De Franciscis, Vittorio ; Vecchio, Giancarlo ; Santelli, Giovanni. / Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter : KRAS expression in thyroids analyzed by in situ hybridization. In: Oncology Research. 1996 ; Vol. 8, No. 2. pp. 85-93.
@article{98df39f9598a47feb16ac8110caa709d,
title = "Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter: KRAS expression in thyroids analyzed by in situ hybridization",
abstract = "We have previously generated transgenic mice bearing a molecular construct obtained by fusing the rat thyroglobulin promoter with the human Kirsten ras oncogene (KRAS). These mice showed thyroid abnormalities, although at very low incidence and after a long latency period. A six-month thyrotropin (TSH) stimulation of thyroid glands, followed by a two-month suspension, induced a significant increase in the number of lesions in transgenic mice as compared with a nontransgenic control group. Our goal was to follow the progression and the reversion of the tumorigenesis process in relationship with the levels of expression of the KRAS in this experimental model. In situ hybridization was used to detect expression of KRAS mRNA in sections of thyroids of the various groups of mice. A positive hybridization was observed in follicular cells of TSH-stimulated transgenic mice, whereas no expression could be appreciated in control nontransgenic mice. A positive signal was also observed in thyroid glands excised from transgenic mice after the 2- month suspension of treatment; however, the number of expressing cells was decreased compared with transgenic mice killed immediately after 6 months of a goitrogen regimen. Finally, every cell in the single thyroid carcinoma observed after the two-month suspension was positive for the transgene mRNA. This study further strengthens the role of the expression of mutated KRAS in the early stages of thyroid follicular cell transformation and indicates that when the expression of the mutated KRAS becomes independent of exogenous TSH stimulation, this event coincides with a further progression towards tumorigenesis.",
keywords = "in situ hybridization, KRAS, thyroid, transgenic mice",
author = "Gennaro Chiappetta and Nicole Fabien and Alessandro Picone and Daniela Califano and Carmen Monaco and {De Franciscis}, Vittorio and Giancarlo Vecchio and Giovanni Santelli",
year = "1996",
language = "English",
volume = "8",
pages = "85--93",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "2",

}

TY - JOUR

T1 - Transgenic mice carrying the human KRAS oncogene under the control of a thyroglobulin promoter

T2 - KRAS expression in thyroids analyzed by in situ hybridization

AU - Chiappetta, Gennaro

AU - Fabien, Nicole

AU - Picone, Alessandro

AU - Califano, Daniela

AU - Monaco, Carmen

AU - De Franciscis, Vittorio

AU - Vecchio, Giancarlo

AU - Santelli, Giovanni

PY - 1996

Y1 - 1996

N2 - We have previously generated transgenic mice bearing a molecular construct obtained by fusing the rat thyroglobulin promoter with the human Kirsten ras oncogene (KRAS). These mice showed thyroid abnormalities, although at very low incidence and after a long latency period. A six-month thyrotropin (TSH) stimulation of thyroid glands, followed by a two-month suspension, induced a significant increase in the number of lesions in transgenic mice as compared with a nontransgenic control group. Our goal was to follow the progression and the reversion of the tumorigenesis process in relationship with the levels of expression of the KRAS in this experimental model. In situ hybridization was used to detect expression of KRAS mRNA in sections of thyroids of the various groups of mice. A positive hybridization was observed in follicular cells of TSH-stimulated transgenic mice, whereas no expression could be appreciated in control nontransgenic mice. A positive signal was also observed in thyroid glands excised from transgenic mice after the 2- month suspension of treatment; however, the number of expressing cells was decreased compared with transgenic mice killed immediately after 6 months of a goitrogen regimen. Finally, every cell in the single thyroid carcinoma observed after the two-month suspension was positive for the transgene mRNA. This study further strengthens the role of the expression of mutated KRAS in the early stages of thyroid follicular cell transformation and indicates that when the expression of the mutated KRAS becomes independent of exogenous TSH stimulation, this event coincides with a further progression towards tumorigenesis.

AB - We have previously generated transgenic mice bearing a molecular construct obtained by fusing the rat thyroglobulin promoter with the human Kirsten ras oncogene (KRAS). These mice showed thyroid abnormalities, although at very low incidence and after a long latency period. A six-month thyrotropin (TSH) stimulation of thyroid glands, followed by a two-month suspension, induced a significant increase in the number of lesions in transgenic mice as compared with a nontransgenic control group. Our goal was to follow the progression and the reversion of the tumorigenesis process in relationship with the levels of expression of the KRAS in this experimental model. In situ hybridization was used to detect expression of KRAS mRNA in sections of thyroids of the various groups of mice. A positive hybridization was observed in follicular cells of TSH-stimulated transgenic mice, whereas no expression could be appreciated in control nontransgenic mice. A positive signal was also observed in thyroid glands excised from transgenic mice after the 2- month suspension of treatment; however, the number of expressing cells was decreased compared with transgenic mice killed immediately after 6 months of a goitrogen regimen. Finally, every cell in the single thyroid carcinoma observed after the two-month suspension was positive for the transgene mRNA. This study further strengthens the role of the expression of mutated KRAS in the early stages of thyroid follicular cell transformation and indicates that when the expression of the mutated KRAS becomes independent of exogenous TSH stimulation, this event coincides with a further progression towards tumorigenesis.

KW - in situ hybridization

KW - KRAS

KW - thyroid

KW - transgenic mice

UR - http://www.scopus.com/inward/record.url?scp=0029927950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029927950&partnerID=8YFLogxK

M3 - Article

C2 - 8859779

AN - SCOPUS:0029927950

VL - 8

SP - 85

EP - 93

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 2

ER -